Maureen Newman,  —

Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Articles by Maureen Newman

Sanofi Opens Recruitment for IPF Clinical Trial

A currently recruiting Phase 2 clinical trial from Sanofi, “Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR),” will be investigating how a novel antibody treatment may help patients with idiopathic pulmonary fibrosis (IPF). The novel therapeutic,…

ProMetic’s Experimental IPF Therapy PBI-4050 Demonstrates Anti-Fibrotic Properties in Human Cells

ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary fibrosis. Two presentations at the 2015 European Renal Association Annual Meeting identified that PBI-4050 reduces fibrosis in human cells. “Our data correlates the regulation activity of PBI-4050 on key fibrotic…

Two Gene Mutations Linked with Telomeres in Pulmonary Fibrosis

Hard at work in the laboratory of Dr. Christine Kim Garcia, Associate Professor of Internal Medicine at UT Southwestern Medical Center, is a group of researchers studying familial pulmonary fibrosis. The disease is characterized by fatal lung scarring and is now associated with mutations in two genes: PARN and RTEL1.